ClinicalTrials.gg
Active, not recruitingNCT06912100Updated Aug 13, 2026

L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation

An Early Phase 1 interventional study of Placebo and Probiotic in Overweight (BMI > 25) and Obese, Otherwise Healthy Volunteers, sponsored by University of Connecticut. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by University of Connecticut · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing probiotic in Overweight — 2 open to participants now, 4 under way, none of them phase 3. Probiotic · Overweight.

Planned enrollment
10th of 12
12 · median 69
Started
2025
with 3 others
Phase 1
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
University of Connecticut

Among the 12 studies testing probiotic in Overweight, this one is the 10th largest by planned enrollment, is one of 4 that started in 2025, is the only one in phase 1, and was the 10th registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

2 of the 12 studies testing probiotic in Overweight are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing probiotic in Overweight, or all of them as a file.
02

Study summary

This is a pilot research study to investigate the effects of a probiotic supplement (L. acidophilus, strain TW01) on substances found in the stool and bloodstream, gut bacteria composition, body composition, as well as any relationship of these substances with markers of inflammation. Lactobacillus acidophilus is commonly found in a variety of fermented foods, including yogurt, cheese, and kefir, due to its ability to produce lactic acid and other substances. This bacterium is generally well-tolerated in healthy individuals and has a longstanding history of safe use. The investigators are doing this pilot study to see if a particular probiotic, called L. acidophilus (strain TW01) and isolated from fermented coffee grounds, can make a positive difference in human gut and overall health. Specifically, the investigators want to look at how this probiotic affects certain substances in human stool and blood, the makeup of the bacteria in the gut, and aspects of body composition. The investigators are also interested in whether these changes relate to markers of inflammation, which can tell us more about their impact on overall health. This probiotic strain has been shown in other studies to be safe and well tolerated, and the investigators hope our research will help us better understand how it works and whether it might support health in humans.

03

Conditions studied

  • Overweight (BMI > 25)
  • Obese, Otherwise Healthy Volunteers

Keywords

  • obesity
  • probiotics
  • gut health
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-60 years
  2. (BMI) between 28 kg/m2 and 40 kg/m2
  3. Waist circumference ≥ 88 cm or 35 inches for women, ≥ 102 cm or 40 inches for men
  4. Willing to consume experimental capsules daily
  5. Willing to prepare and consume the delivered meal kits
  6. Do not fit any exclusion criteria

Exclusion criteria

Exclusion Criteria:

  1. Self-reported history of immunodeficiency, major gastrointestinal surgery, renal or liver disease, diabetes, heart disease, stroke, peripheral artery/vascular disease, cancer, eating disorders, gut-associated pathologies, diseases, pacemaker, thyroid disease, gallbladder disease, chronic inflammatory diseases, scleroderma, blood clotting disorders, intravenous drug use
  2. Weight changes > 10% over the last 4 weeks
  3. Oral antibiotics and/or probiotics use up to 1 month prior to study and during study
  4. Currently taking GLP-1 analogues (e.g., Ozempic), anti-inflammatory medications (e.g., ), daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) (occasional use is permitted), medications which primarily affect blood clotting (e.g., warfarin), or any medications that suppress the immune system.
  5. Dairy allergy
  6. Currently pregnant or breast-feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (estimated)

Study arms

  • Placebo comparator
    Placebo phase

    Participants consume capsules containing only an inactive placebo (maltodextrin and magnesium stearate).

    Dietary Supplement: Placebo

  • Experimental
    Probiotic phase

    Participants consume capsules containing L. acidophilus (TW01) at 4×10\^10 CFU/capsule (three capsules daily, totaling 1.2×10\^11 CFU/day) plus a commercial fiber source (Fibersol-2).

    Dietary Supplement: Probiotic

Interventions

  • Dietary supplementPlacebo

    Participants consume capsules containing only an inactive placebo (maltodextrin and magnesium stearate).

  • Dietary supplementProbiotic

    Participants consume capsules containing L. acidophilus (TW01) at 4×10\^10 CFU/capsule (three capsules daily, totaling 1.2×10\^11 CFU/day) plus a commercial fiber source (Fibersol-2).

06

What researchers measure

Primary outcomes

  1. Fecal butyrate

    Determine the effects of the probiotic on the short-chain fatty acid, butyrate (mmol/L), a marker of gut health in stool

    Time frame: From baseline to the end of each 6-week intervention phase

Secondary outcomes

  1. Serum inflammation marker

    Determine the effects of the probiotic on a marker of inflammation, high-sensitivity C-reactive protein (hsCRP) (mg/L), in the bloodstream

    Time frame: From baseline to the end of each 6-week intervention phase

  2. Body fat composition

    Determine the effects of the probiotic on body fat composition by bioelectric impedance analysis (% of body weight).

    Time frame: From baseline to end of each 6-week intervention phase

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Only IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 234 phase 1 interventional studies under Overweight, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 4, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06912100
Responsible party
Christopher Blesso (Associate Professor, University of Connecticut) — Principal investigator
First posted
Apr 4, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion